Skip to menu Skip to content Skip to footer
Professor Maher Gandhi
Professor

Maher Gandhi

Email: 

Overview

Background

Maher Gandhi received his medical degree in the UK in 1989, and then trained as a haematologist, including a Fellowship in malignant haematology at Princess Margaret Cancer Centre, Toronto. He was awarded a PhD in immunology at Cambridge University under Patrick Sissons. He moved to Brisbane and from 2003-2024 worked as a Senior Staff Specialist (Pre-Eminent Status) in the Haematology / Oncology Department of the Princess Alexandra Hospital. He leads his own laboratory group and has established an international reputation studying the tumour immune microenvironment in lymphoma and its manipulation, with continuous NHMRC/MRFF funding since 2005. He was Chair of Laboratory Sciences for the Australasian Leukaemia and Lymphoma Group between 2010-2016, won the prestigious Australian Society of Medical Research Clinical Research Award in 2010 and in 2012 took up the inaugural John McCaffrey Cancer Council of Queensland / Office of Health and Medical Research Clinical Research Fellowship. Between 2011-2014 he was privileged to serve as Chair of the Metro South Human Research Ethics Committee. In 2013 he was appointed Professor of Experimental Haematology, University of Queensland, based at the Translational Research Institute, in 2014 became the inaugural Leukaemia Foundation Chair of Blood Cancer Research at the University of Queensland Frazer Institute, and was appointed Cancer Program Head in 2016. In 2018 he became Executive Director and Director of Clinical Research at Mater Research. He also continues to head the Blood Cancer Research Group, which is based in Mater Research. In 2025 to current, he was appointed Chief Executive Officer of the Translational Research Institute and its manufacturing branch TM@TRI, to serve Queenslanders by transforming health through collaborative research.

Availability

Professor Maher Gandhi is:
Available for supervision
Media expert

Qualifications

  • Bachelor of Medicine Surgery, University of Aberdeen
  • Doctor of Philosophy, University of Cambridge

Research interests

  • Lymphoma

  • Immunotherapy

  • Biomarkers

Research impacts

The research of the Blood Cancer Research Laboratory aims to understand the basis of lymphoma; to devise new treatments which are less toxic and more effective; to establish new biomarkers which will help determine the most effective treatment strategies and to monitor response and relapse and understand the development of lymphomas. The group has a strong emphasis on patient material, which it obtains from international and national clinical collaborators. Lymphomas studied includeEBV-associated lymphomas, Hodgkin Lymphoma, PTLD, Diffuse Large B-cell Lymphoma, Follicular Lymphoma and amyloidosis. We utilise a broad range of approaches including genomics, transcriptomics and functional immunoassays, and are conducting a number of MRFF funded cellular therapy studies sponsored by the Australasian Leukaemia and Lymphoma Group.

The Mater Foundation, the Leukaemia Foundation, the Mark Coghlan EBV Lymphoma Project and the Brisbane Girls Grammar School Kirsten Jack Memorial Fund are thanked for their kind support.

Works

Search Professor Maher Gandhi’s works on UQ eSpace

224 works between 1993 and 2024

141 - 160 of 224 works

2011

Journal Article

Optimizing tumor-targeting chimeric antigen receptor T cells in B-cell lymphoma patients

Gandhi, M. and Jones, K. (2011). Optimizing tumor-targeting chimeric antigen receptor T cells in B-cell lymphoma patients. Immunotherapy, 3 (12), 1441-1443. doi: 10.2217/IMT.11.135

Optimizing tumor-targeting chimeric antigen receptor T cells in B-cell lymphoma patients

2011

Journal Article

A novel immunodeficiency disorder characterized by genetic amplification of interleukin 25

Green, M. R., Camilleri, E., Gandhi, M. K., Peake, J. and Griffiths, L. R. (2011). A novel immunodeficiency disorder characterized by genetic amplification of interleukin 25. Genes and Immunity, 12 (8), 663-666. doi: 10.1038/gene.2011.50

A novel immunodeficiency disorder characterized by genetic amplification of interleukin 25

2011

Conference Publication

A Multi-Centre, Single-Arm, Open-Label Study Evaluating the Safety and Efficacy of Fixed Dose Rituximab in Patients with Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura (R-ITP1000 Study) and Exploring Rituximab Response with the FcGammaR3A Polymorphisms

Huyen Tran, , Nourse, Jamie P., Lea, Rod, Brighton, Timothy A., Grigg, Andrew, McRae, Simon, Thurley, Daniel, Gandhi, Maher and Catalano, John (2011). A Multi-Centre, Single-Arm, Open-Label Study Evaluating the Safety and Efficacy of Fixed Dose Rituximab in Patients with Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura (R-ITP1000 Study) and Exploring Rituximab Response with the FcGammaR3A Polymorphisms. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego Ca, Dec 10-13, 2011. WASHINGTON: AMER SOC HEMATOLOGY.

A Multi-Centre, Single-Arm, Open-Label Study Evaluating the Safety and Efficacy of Fixed Dose Rituximab in Patients with Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura (R-ITP1000 Study) and Exploring Rituximab Response with the FcGammaR3A Polymorphisms

2011

Journal Article

Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes

Nguyen-Van, Do, Keane, Colm, Han, Erica, Jones, Kimberley, Nourse, Jamie P., Vari, Frank, Ross, Nathan, Crooks, Pauline, Ramuz, Olivier, Green, Michael, Griffith, Lyn, Trappe, Ralf, Grigg, Andrew, Mollee, Peter and Gandhi, Maher K. (2011). Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes. American Journal of Blood Research, 1 (2), 146-159.

Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes

2011

Journal Article

Broad-spectrum immunosuppression by classless monocytes in non-Hodgkin's lymphoma

Vari, F. and Gandhi, M.K. (2011). Broad-spectrum immunosuppression by classless monocytes in non-Hodgkin's lymphoma. Immunotherapy, 3 (6), 723-726. doi: 10.2217/IMT.11.56

Broad-spectrum immunosuppression by classless monocytes in non-Hodgkin's lymphoma

2011

Journal Article

Molecular mechanisms influencing NK cell development: implications for NK cell malignancies.

Mujaj, Sally A., Spanevello, Michelle M., Gandhi, Maher K. and Nourse, Jamie P. (2011). Molecular mechanisms influencing NK cell development: implications for NK cell malignancies.. American Journal of Blood Research, 1 (1), 34-45.

Molecular mechanisms influencing NK cell development: implications for NK cell malignancies.

2011

Journal Article

Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin's lymphoma

Green, Michael R., Aya-Bonilla, Carlos, Gandhi, Maher K., Lea, Rod A., Wellwood, Jeremy, Wood, Peter, Marlton, Paula and Griffiths, Lyn R. (2011). Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin's lymphoma. Genes Chromosomes and Cancer, 50 (5), 313-326. doi: 10.1002/gcc.20856

Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin's lymphoma

2011

Journal Article

Epstein-Barr virus-related post-transplant lymphoproliferative disorders: Pathogenetic insights for targeted therapy

Nourse, J. P., Jones, K. and Gandhi, M. K. (2011). Epstein-Barr virus-related post-transplant lymphoproliferative disorders: Pathogenetic insights for targeted therapy. American Journal of Transplantation, 11 (5), 888-895. doi: 10.1111/j.1600-6143.2011.03499.x

Epstein-Barr virus-related post-transplant lymphoproliferative disorders: Pathogenetic insights for targeted therapy

2011

Conference Publication

Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6

Keane, C, Shen, L, Han, E, Nourse, JP, Lea, R, Mollee, P, Gill, DS and Gandhi, MK (2011). Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego Ca, Dec 10-13, 2011. WASHINGTON: AMER SOC HEMATOLOGY.

Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6

2011

Conference Publication

Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL

Gandhi, MK, Hertzberg, MS, Han, E, Seymour, JF, Hicks, R, Gill, DS, Keane, C, Crooks, P, Radford, K and Vari, F (2011). Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego Ca, Dec 10-13, 2011. WASHINGTON: AMER SOC HEMATOLOGY.

Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL

2011

Conference Publication

Tissue microarray in DLBCL patients receiving CHOP-R chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6 and poor outcome for EBER-ISH positive patients

Keane, C., Shen, L., Nourse, J., Han, E., Jones, K. and Gandhi, M. (2011). Tissue microarray in DLBCL patients receiving CHOP-R chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6 and poor outcome for EBER-ISH positive patients. 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, 15-18 June 2011. Oxford, United Kingdom: Oxford University Press.

Tissue microarray in DLBCL patients receiving CHOP-R chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6 and poor outcome for EBER-ISH positive patients

2010

Journal Article

Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders

Jones, Kimberley, Nourse, Jamie P., Morrison, Leanne, Nguyen-Van, Do, Moss, Denis J., Burrows, Scott R. and Gandhi, Maher K. (2010). Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders. Blood, 116 (13), 2245-2252. doi: 10.1182/blood-2010-03-274076

Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders

2010

Journal Article

Can a blood test monitor lymphoma?

Jones, Kimberley and Gandhi, Maher K. (2010). Can a blood test monitor lymphoma?. Leukemia and Lymphoma, 51 (6), 957-959. doi: 10.3109/10428194.2010.487623

Can a blood test monitor lymphoma?

2010

Journal Article

Fulminant infectious mononucleosis and recurrent epstein-barr virus reactivation in an adolescent

Nourse, Jamie P., Jones, Kimberley, Dua, Ujjwal, Runnegar, Naomi, Looke, David, Schmidt, Chris, Tey, Siok-Keen, Kennedy, Glen and Gandhi, Maher K. (2010). Fulminant infectious mononucleosis and recurrent epstein-barr virus reactivation in an adolescent. Clinical Infectious Diseases, 50 (6), e34-e37. doi: 10.1086/650007

Fulminant infectious mononucleosis and recurrent epstein-barr virus reactivation in an adolescent

2010

Journal Article

Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity

Jones, K., Nourse, J., Corbett, G. and Gandhi, M. K. (2010). Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity. International Journal of Laboratory Hematology, 32 (1p1), e169-e174. doi: 10.1111/j.1751-553X.2008.01130.x

Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity

2010

Conference Publication

Ebv-Positive Dlbcl of the Elderly Is a Distinct Clinico-Biological Entity with Poor Outcome in Chop-R Treated Patients

Gandhi, M., Keane, C., Nourse, J., Jones, K., Ross, N., Han, E. and Nguyen-Van, D. (2010). Ebv-Positive Dlbcl of the Elderly Is a Distinct Clinico-Biological Entity with Poor Outcome in Chop-R Treated Patients. 15th Annual Meeting of the European-Hematology-Association, Barcelona Spain, June 10-13, 2010. Pavia, Italy: Fondazione Ferrata Storti.

Ebv-Positive Dlbcl of the Elderly Is a Distinct Clinico-Biological Entity with Poor Outcome in Chop-R Treated Patients

2009

Conference Publication

EBV MicroRNA Expression in Virus Driven B-Cell Differentiation and Lymphomagenesis

Nourse, Jamie P., Crooks, Pauline, Van, Do Nguyen, Jones, Kimberley, Ross, Nathan and Gandhi, Maher K. (2009). EBV MicroRNA Expression in Virus Driven B-Cell Differentiation and Lymphomagenesis. 51st Annual Meeting of the American-Society-of-Hematology, New Orleans La, Dec 05-08, 2009. WASHINGTON: AMER SOC HEMATOLOGY.

EBV MicroRNA Expression in Virus Driven B-Cell Differentiation and Lymphomagenesis

2009

Conference Publication

Cell-free Epstein-Barr Virus DNA is a Specific Biomarker for Tumor Burden in EBV-associated Lymphomas

Jones, Kimberley, Nourse, J., Crooks, P., Gottlieb, D. and Gandhi, Mahei (2009). Cell-free Epstein-Barr Virus DNA is a Specific Biomarker for Tumor Burden in EBV-associated Lymphomas. 24th Annual Meeting of the International-Society-for-Biology-Therapy-of-Cancer, Washington Dc, Oct 29-31, 2009. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Cell-free Epstein-Barr Virus DNA is a Specific Biomarker for Tumor Burden in EBV-associated Lymphomas

2009

Conference Publication

Epstein-Barr Virus-specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas

Jones, Kimberley, Vari, Frank, Khanna, Rajiv, Han, Erica, Singh, Sanjleena, Ritchie, David and Gandhi, Maher K. (2009). Epstein-Barr Virus-specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas. 24th Annual Meeting of the International-Society-for-Biology-Therapy-of-Cancer, Washington Dc, Oct 29-31, 2009. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Epstein-Barr Virus-specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas

2009

Conference Publication

Mechanisms Underlying the Selective Impairment of Epstein Barr Virus-Nuclear Antigen I-specific Effector T Cells Observed in PTLD

Jones, Kimberley, Nouise, J., Morrison, L., Vari, Frank, Moss, D. and Gandhi, Mahei K. (2009). Mechanisms Underlying the Selective Impairment of Epstein Barr Virus-Nuclear Antigen I-specific Effector T Cells Observed in PTLD. 24th Annual Meeting of the International-Society-for-Biology-Therapy-of-Cancer, Washington Dc, Oct 29-31, 2009. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Mechanisms Underlying the Selective Impairment of Epstein Barr Virus-Nuclear Antigen I-specific Effector T Cells Observed in PTLD

Funding

Current funding

  • 2025 - 2027
    Personalized immunotherapy for the treatment of light chain amyloidosis
    Snowdome Haematology Fellowship
    Open grant
  • 2024 - 2029
    BrainCAR19 Study- Treatment of relapsed Primary Brain Lymphoma with CD19 directed CAR-T cells
    NHMRC MRFF CTA - Clinical Trials Activity
    Open grant
  • 2023 - 2025
    Metabolic Reprogramming of Malignant B-cells Impairs Immune-Fitness of Intratumoral T-Cells in Follicular Lymphoma
    Conquer Cancer AstraZeneca Young Investigator Award
    Open grant
  • 2019 - 2026
    An Open Label, Multicentre, Phase One Study Incorporating Early Application of CAR T cells for Primary Refractory Aggressive Lymphoma
    NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need
    Open grant
  • 2018 - 2025
    An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies
    NHMRC MRFF - Lifting Clinical Trials Registries Capacity
    Open grant

Past funding

  • 2020 - 2022
    PiggyBac transposon UCB-CAR19-NK cells: a novel off-the-shelf cellular immunotherapy for children with CD19+ blood cancers
    Children's Hospital Foundation Immunotherapy Research Grants
    Open grant
  • 2019 - 2020
    Indolent Lymphoma: Establishing a prognostic score fit for the modern era
    The Leukaemia Foundation of Australia Limited
    Open grant
  • 2018 - 2019
    A novel immunotherapy strategy for lymphoma using artificial microRNA gene targeting
    Metro South Hospital and Health Service
    Open grant
  • 2018 - 2022
    Integrating immunity and genetics in Follicular Lymphoma to establish a prognostic score fit for the modern era
    NHMRC Project Grant
    Open grant
  • 2017 - 2019
    Pre-clinical studies of anti-LAG3 in lymphoma
    Bristol-Myers Squibb Pharmaceuticals Pty Limited
    Open grant
  • 2017
    Improving the evidence base for resource allocation in indolent lymphoma
    Gilead Australia Fellowship
    Open grant
  • 2016 - 2018
    Prognosticator for Follicular lymphoma (FL) and Mantle celly lymphoma (MCL)
    Research Donation Generic
    Open grant
  • 2016 - 2017
    Blood biomarkers in Hodgkin Lymphoma
    PA Research Foundation NHMRC Infrastructure Support
    Open grant
  • 2016
    Marshaling NK-cells in the fight against blood cancers: a novel approach
    PA Research Foundation NHMRC Near Miss Grant
    Open grant
  • 2015 - 2016
    Funding Assistance for Gandhi laboratory
    Metro South Hospital and Health Service
    Open grant
  • 2015 - 2016
    Using single-cell transcriptomics to define T-cell tolerance in EBV+ lymphoma
    PA Research Foundation
    Open grant
  • 2014 - 2018
    Leukaemia Foundation Queensland Chair in Blood Cancer Research (2014-2019)
    Leukaemia Foundation
    Open grant
  • 2014 - 2017
    Circulating Biomarkers in advanced classical Hodgkin Lymphoma
    NHMRC Project Grant
    Open grant
  • 2013 - 2020
    The Diamantina Individualised Oncology Care Centre (DIOCC)
    Australian Cancer Research Foundation
    Open grant
  • 2013 - 2014
    Monocytic myeloid derived suppressor cells and antiCD20-antibody dependent cellular cytotoxicity in diffuse large B-cell lymphoma (Cancer Council Queensland grant administered by PAH)
    Metro South Hospital and Health Service
    Open grant

Supervision

Availability

Professor Maher Gandhi is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Completed supervision

Media

Enquiries

Contact Professor Maher Gandhi directly for media enquiries about:

  • Biomarkers
  • Immunotherapy
  • Lymphoma

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au